Clinical Trial Update: A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetics and safety of NKTR-102 (etirinotecan pegol) in cancer patients with hepatic impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• NKTR-102

Snippet

Sponsor: Nektar Therapeutics | Conditions: Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | Phase 1 | Status: COMPLETED